(一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定; (三)中央纪委、中央组织部《关于规范中管干部辞去公职或者退(离)休后担任 上市公司、基金管理公司独立董事、独立监事的通知》的规定; (四)中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的意见》关于 高校领导班子成员兼任职务的规定; 广州维力医疗器械股份有限公司独立董事候选人声明 本人芦春斌,已充分了解并同意由提名人广州维力医疗器械股份有限公司董事会提 名为广州维力医疗器械股份有限公司(以下简称"该公司")第五届董事会独立董事候 选人。本人公开声明,本人具备独立董事任职资格,保证不存在任何影响本人担任该公 司独立董事独立性的关系,具体声明如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法规、规章及其他规 范性文件,具有五年以上法律、经济、财务、管理或者其他履行独立董事职责所必需的 工作经验。本人尚未根据《上市公司高级管理人员培训工作指引》及相关规定取得独立 董事资格证书。本人承诺在本次提名后,参加上海证券交易所举办的最近一期独立董事 资格培训并取得独立董事资格证书。 二、本人 ...

广州维力医疗器械股份有限公司独立董事 关于第四届董事会第二十一次会议相关事项的独立意见 根据《上市公司独立董事规则》《上市公司治理准则》《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第1号——规范运作》和 《公司章程》等有关文件规定，我们作为广州维力医疗器械股份有限公司（以下 简称"维力医疗"、"公司"）独立董事，在认真审阅相关材料的基础上，就公 司第四届董事会第二十一次会议审议的相关议案发表如下独立意见： 一、关于《公司募集资金存放与实际使用情况的专项报告（2023年半年度）》 的独立意见 经核查，《公司募集资金存放与实际使用情况的专项报告（2023年半年度）》 符合《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所上市公司自律监管指引第1号——规范运作》等有关规定，该 报告对公司2023年上半年度募集资金的管理情况、实际使用情况、变更募投项目 的资金使用情况以及募集资金在使用中存在的问题等作出了充分详细的说明，真 实、客观反映了公司2023年半年度募集资金存放与实际使用情况，不存在募集资 金存放和使用违规的情形，不存在损害公司和全体股东特别是中小投资 ...

证券代码：603309 证券简称：维力医疗 公告编号：2023-037 广州维力医疗器械股份有限公司 | 修订前 | 修订后 | | --- | --- | | 第六条 公司注册资本为人民币29,332.2218万 | 第六条 公司注册资本为人民币 29,316.0218 万元。 | | 元。 | | | 公司发行的股票，以人民币标明面值。 第十七条 | 第十七条 公司发行的股票，以人民币标明面值，每 | | | 股面值为人民币一元。 | | 第十九条 | | 公司设立时发起人认购股份情况如 | | 第十九条 | | | 公司设立时发起人认购股份情况如下： | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 下： | | | | 序 | | 持股数 | 持股比 | 出资方 | | | | | | | | 发起人 | | 例 | | 出资时间 | | | | | | 号 | | （万股） | （%） | 式 | | | 序号 | 发起人 | 持股数（万 | 持股比例 | | 高博投资（香港）有限公 | | | | | | | ...

证券代码：603309 证券简称：维力医疗 公告编号：2023-039 上述候选人已征得其本人同意。上述独立董事候选人已通过上海证券交易所 独立董事资格备案审查。所有董事候选人将提交公司股东大会审议，股东大会选 举产生新一届董事会之前，公司第四届董事会继续履行职责。 二、监事会换届选举情况 1、非职工代表监事 广州维力医疗器械股份有限公司 关于董事会、监事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广州维力医疗器械股份有限公司（以下简称"公司""维力医疗"）第四届 董事会、第四届监事会任期即将届满，根据《公司法》《证券法》《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号—规范运作》 等法律法规、规范性文件以及《公司章程》的相关规定，公司开展了董事会、监 事会换届选举工作。现将相关情况公告如下： 一、董事会换届选举情况 公司于2023年8月8日召开的第四届董事会第二十一次会议审议通过了《关于 公司董事会换届选举的议案》。公司第四届董事会提名向彬先生、韩广源先生、 段嵩枫先生、 ...

证券代码：603309 证券简称：维力医疗 公告编号：2023-030 广州维力医疗器械股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播结合网络文字互动 投资者可于 2023 年 5 月 12 日(星期五)至 5 月 18 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 visitor@welllead.com.cn 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 广州维力医疗器械股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日发布公司 2022 年年度报告及 2023 年第一季度报告，为便于广大投资者更全面 深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 5 月 19 日上午 11：00-12：00 举行 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,363,352,554.01, representing a 21.88% increase compared to CNY 1,118,570,938.92 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 166,571,286.53, a 57.00% increase from CNY 106,093,288.87 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 145,716,799.22, up 45.38% from CNY 100,230,278.16 in 2021[22]. - The net cash flow from operating activities was CNY 391,125,593.85, an increase of 108.84% compared to CNY 187,283,077.81 in 2021[22]. - Basic earnings per share rose by 39.02% to CNY 0.57 in 2022 compared to CNY 0.41 in 2021[24]. - The weighted average return on equity improved by 1.00 percentage points to 10.14% in 2022[24]. - The company reported a quarterly operating revenue of CNY 374.32 million in Q3 2022, with a net profit of CNY 55.19 million for the same period[27]. - The company achieved operating revenue of RMB 1,363.35 million, a year-on-year increase of 21.88%, and a net profit attributable to shareholders of RMB 166.57 million, up 57.00%[32]. - The company reported a net loss from investment activities of approximately 560 million, which is a deterioration compared to the previous year's loss of 156 million[79]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 3.4 per 10 shares, totaling CNY 99,729,554.12 based on the total share capital of 293,322,218 shares as of April 19, 2023[5]. - The company does not plan to increase capital reserves to share capital for the 2022 fiscal year, with undistributed profits carried forward to the next fiscal year[5]. - The company has established a clear cash dividend policy and has adhered to it from 2015 to 2022, ensuring the protection of minority shareholders' rights[146]. - The company distributed a cash dividend of 3.4 CNY per 10 shares, totaling 99,729,554.12 CNY, which represents 59.87% of the net profit attributable to ordinary shareholders in the consolidated financial statements[148]. - The company has not proposed a cash profit distribution plan for the reporting period, as it is not applicable[147]. Market and Product Development - Main business revenue reached RMB 1,353.72 million, growing by 22.41%, with anesthesia product revenue at RMB 409.45 million (up 17.30%) and urinary products revenue at RMB 424.19 million (up 46.07%) [32]. - The company’s domestic sales revenue was RMB 707.71 million, reflecting a year-on-year growth of 17.90%[34]. - The company’s international sales revenue reached RMB 646.01 million, a year-on-year increase of 27.76%, with North America and Europe markets growing by 25.24% and 38.66% respectively[35]. - Six new products received domestic medical device registration, and two products obtained FDA approval in the U.S.[37]. - The company completed the acquisition of a 51.47% stake in Suzhou Maide Xun, enhancing its product offerings in pain and infusion management[39]. - The company invested in 13 automation projects to improve production efficiency and product quality stability[40]. - The company has established a strong presence in over 5,000 hospitals across China, including more than 1,000 top-tier hospitals, and holds over 300 medical device registrations globally[47]. - The company is focusing on expanding its market presence through new product registrations and potential acquisitions in the medical device sector[85]. Research and Development - Research and development expenses increased by 49.15% to 82,073,867.39 CNY, reflecting the company's commitment to innovation[63]. - The company holds 247 patents, including 23 authorized invention patents, showcasing its leading technology level[60]. - The company has several ongoing R&D projects, including a third-generation circumcision suturing device with an investment of RMB 14.41 million[93]. - The company is currently validating a dual-lumen non-inflatable laryngeal mask, with an investment of RMB 4.69 million[93]. - R&D investment for Yuyue Medical reached RMB 425.67 million, accounting for 6.17% of total revenue[91]. Corporate Governance and Compliance - The company has conducted six board meetings and five supervisory meetings during the reporting period, ensuring compliance with governance regulations[114][115]. - The company has maintained independence from its controlling shareholders and actual controllers, with no reported conflicts of interest or competitive business activities[118]. - The company has established a strict insider information management system to prevent insider trading, ensuring accurate and complete records of insider information disclosure[117]. - The company has not faced any penalties from securities regulatory agencies in the past three years[131]. - The company has implemented a performance evaluation mechanism for senior management, which is overseen by the remuneration and assessment committee[151]. Environmental Responsibility - The company has invested 1.3052 million yuan in environmental protection during the reporting period[157]. - The company has a wastewater treatment facility and 11 sets of organic waste gas treatment facilities, all operating normally and meeting discharge standards[159]. - The company has reported no significant environmental issues or administrative penalties during the reporting period[158]. - The company has implemented measures to address ecological protection and pollution prevention during the reporting period[165]. - The company has established an environmental emergency response plan, which was revised in November 2021 and filed with the local environmental protection bureau[161]. Financial Management - The company reported a total guarantee amount of 28,000.00 million RMB, which accounts for 16.09% of the company's net assets[186]. - The company has a total of 29,550.00 million RMB in investment management, with an outstanding balance of 28,000.00 million RMB[188]. - The company has completed cash recovery from various bank financial products, achieving an annualized return rate of up to 6.00%[189]. - The company successfully issued 29,632,218 shares at a price of 13.48 yuan per share, raising a total of 399.44 million yuan[200]. - The company has ongoing financial products with a total value of 2,900 million, set to mature on March 31, 2023, with an interest rate of 2.52%[194].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 361,577,520.44, representing a year-on-year increase of 20.16%[3] - The net profit attributable to shareholders for the same period was CNY 52,097,979.79, reflecting a growth of 34.92% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 47,333,866.04, up by 36.35% year-on-year[3] - Basic earnings per share for Q1 2023 were CNY 0.18, an increase of 38.46% compared to the same period last year[3] - Operating profit for Q1 2023 was ¥72,315,240.14, up 41.4% from ¥51,109,848.62 in Q1 2022[15] - Net profit attributable to shareholders of the parent company was ¥52,097,979.79, representing a 35% increase from ¥38,612,671.22 in Q1 2022[16] - The company reported a total comprehensive income of ¥57,766,277.96 for Q1 2023, compared to ¥41,416,184.78 in Q1 2022[16] Cash Flow - The net cash flow from operating activities reached CNY 67,675,594.49, showing a significant increase of 139.13%[5] - The net cash flow from operating activities for Q1 2023 was ¥67,675,594.49, a significant increase from ¥28,301,006.76 in Q1 2022, representing a growth of approximately 139.5%[19] - Total cash inflow from investment activities was ¥364,144,218.91, compared to ¥205,314,748.68 in the previous year, indicating an increase of about 77.2%[19] - The net cash flow from investment activities was -¥185,035,220.76, an improvement from -¥350,894,954.10 year-over-year[19] - Cash inflow from financing activities totaled ¥90,000,000.00, up from ¥62,680,988.54 in Q1 2022, marking an increase of approximately 43.7%[20] - The net cash flow from financing activities was ¥42,601,794.97, a decrease from ¥57,691,827.75 in the same quarter last year[20] - The company reported a total cash outflow from operating activities of ¥295,927,774.42, slightly lower than ¥299,380,153.10 in the previous year[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,438,122,662.94, up 2.29% from the end of the previous year[3] - The total current assets reached RMB 1,039,380,009.55, compared to RMB 994,114,382.02 in the previous year, indicating an increase of about 4.6%[11] - The total liabilities stood at RMB 1,039,380,009.55, reflecting a rise from RMB 994,114,382.02, which is an increase of about 4.6%[11] - Total liabilities decreased slightly to ¥640,594,851.89 from ¥643,851,468.73 in the previous period[12] - The total non-current assets amounted to RMB 1,398,742,653.39, slightly up from RMB 1,389,498,619.80, indicating a growth of about 0.2%[11] Shareholder Information - The company reported a total of 15,647 common shareholders at the end of the reporting period[6] - The top shareholder, Gao Bo Investment (Hong Kong) Limited, holds 31.37% of the shares, with 26,000,000 shares pledged[7] - The company reported a total of 3,905,332 shares held by major shareholder Zhou Xinwei, with 3,625,592 shares held through a margin account[9] - Total equity attributable to shareholders of the parent company increased to ¥1,775,966,899.04 from ¥1,723,868,919.25[12] Research and Development - Research and development expenses increased to ¥17,971,542.32, up 37.5% from ¥13,117,131.96 in Q1 2022[15] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[15]

证券代码：维力医疗 证券简称：603309 广州维力医疗器械股份有限公司接待调研记录表 编号：2022001 | --- | --- | --- | |-----------------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 调研形式 | √特定对象调研 □新闻发布会 □ ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 374,316,058.66, representing a year-on-year increase of 28.20%[3] - The net profit attributable to shareholders for Q3 2022 was CNY 55,188,163.08, reflecting a significant increase of 56.69% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was CNY 51,489,672.76, up by 50.48% year-on-year[3] - The net profit attributable to shareholders for the year-to-date period was CNY 137,503,187.70, marking a 68.18% increase year-on-year[3] - Net profit for the first three quarters of 2022 was ¥146,550,717.75, representing a 65.7% increase from ¥88,422,616.59 in 2021[19] Earnings and Shareholder Returns - The basic earnings per share for Q3 2022 was CNY 0.19, an increase of 35.71% compared to the same period last year[4] - The diluted earnings per share for Q3 2022 was also CNY 0.19, reflecting a 35.71% increase year-on-year[4] - Earnings per share for the third quarter of 2022 were ¥0.47, compared to ¥0.31 in the same quarter of the previous year[19] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period reached CNY 262,058,709.96, showing a remarkable increase of 173.83%[3] - Operating cash inflow for the first three quarters of 2022 reached ¥1,157,197,010.56, a 36% increase from ¥850,485,045.77 in the same period of 2021[21] - Net cash flow from operating activities was ¥262,058,709.96, compared to ¥95,699,591.38 in the previous year, marking a significant increase[22] - The ending balance of cash and cash equivalents was ¥237,454,061.16, up from ¥152,120,160.68 in the same period last year[23] - The company reported cash and cash equivalents of ¥237,454,061.16 as of September 30, 2022, down from ¥604,584,094.35 at the end of 2021[12] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to CNY 2,271,288,230.53, representing a growth of 6.52% from the end of the previous year[4] - The total assets as of the end of the third quarter of 2022 amounted to ¥2,271,288,230.53, an increase from ¥2,132,362,965.18 at the end of the previous year[14] - Total liabilities increased to ¥581,157,103.76 from ¥540,870,556.73 year-over-year[14] - The total current assets amount to ¥948,536,357.80, compared to ¥974,541,894.66 at the end of 2021[12] Investments and Expenditures - The company reported an investment income of ¥5,510,407.22, a significant increase from ¥431,062.62 in the previous year[18] - Research and development expenses for the first three quarters of 2022 were ¥52,910,456.51, up 58.8% from ¥33,314,053.73 in the same period of 2021[18] - Total cash outflow for investment activities was ¥1,459,394,041.89, compared to ¥270,181,566.86 in the previous year, indicating increased investment spending[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,535[10] - The largest shareholder, Gaobo Investment (Hong Kong) Limited, holds 92,019,200 shares, representing 31.36% of total shares, with 31,200,000 shares pledged[10] - Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds 44,864,856 shares, accounting for 15.29% of total shares, with 14,800,000 shares pledged[10] Other Notable Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report[11] - There are no significant changes in the shareholder structure or related party transactions reported[11]

Financial Performance - The company's operating revenue for the first half of 2022 reached ¥630,129,678.08, representing a 33.20% increase compared to ¥473,069,251.27 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥82,315,024.62, a significant increase of 76.87% from ¥46,539,417.62 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥74,154,410.48, up 77.25% from ¥41,835,757.71 year-on-year[19]. - The net cash flow from operating activities was ¥158,607,950.05, showing a substantial increase of 140.50% compared to ¥65,950,577.29 in the same period last year[19]. - The company's basic earnings per share increased by 55.56% to CNY 0.28 compared to the same period last year[20]. - Net profit attributable to shareholders increased by CNY 35.78 million, a year-on-year growth of 76.87%, driven by a 33.20% increase in operating revenue[21]. - The diluted earnings per share also increased by 55.56% to CNY 0.28, reflecting the growth in net profit[21]. - The total profit for the first half of 2022 was ¥100,259,689.76, compared to ¥49,809,689.84 in the same period of 2021, marking an increase of 101.0%[143]. Assets and Liabilities - Total assets increased by 4.73%, reaching ¥2,233,161,135.96 compared to ¥2,132,362,965.18 at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,621,184,460.48, reflecting a 2.71% increase from ¥1,578,481,435.29 at the end of the previous year[19]. - The company's total liabilities rose to CNY 602,380,329.97 from CNY 540,870,556.73, indicating an increase of approximately 11.37%[133]. - The company's total equity attributable to shareholders was 1,578,481,435.29 RMB at the end of the reporting period[152]. - The total owner's equity reached CNY 1,630,780,805.99, up from CNY 1,591,492,408.45, reflecting an increase of about 2.46%[133]. Research and Development - The company's R&D expenses rose by 49.77% to RMB 32,017,382.29, reflecting a continuous increase in investment in research and development[53]. - The company is focused on expanding its product lines in the fields of anesthesia, urology, and respiratory care, with significant applications in clinical settings[26]. - R&D investment has been increased to promote product upgrades in niche areas, with collaborations established with several hospitals for joint research[45]. Market and Sales - The company achieved a 33.20% growth in operating revenue, attributed to strong sales from both export and domestic markets despite some regional pandemic impacts[20]. - The overseas sales revenue increased by 57% year-on-year, with North American major client revenue growing by 80%[44]. - The company has established a presence in over 4,000 hospitals across China, including more than 1,000 tier-three hospitals[31]. Environmental Compliance - The company has established wastewater treatment facilities and 11 sets of organic waste gas treatment facilities, all operating normally and meeting discharge standards[88]. - The company has not faced any administrative penalties related to environmental issues[87]. - The company has committed to fulfilling environmental responsibilities and has established measures to reduce carbon emissions, although specific details were not disclosed[92]. Corporate Governance - The company has not disclosed any plans for profit distribution or capital reserve transfer during this reporting period[4]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[5]. - The company has a good integrity status, with no unfulfilled court judgments or significant overdue debts[101]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[138]. - The company is making preparations for potential post-pandemic recovery in overseas markets, including capacity and shipping channel reserves[77]. - The company plans to diversify its market layout and strengthen the management of overseas agents to mitigate sales risks[72].